Jaime Mayoral, MD
Colon & Rectal Surgery · San Antonio, TXNPI 1689677916
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (30.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Pacira Pharmaceuticals Incorporated at 27.4% of the total. 2025 is the largest year on record at $27,193, 2.7 times the $10,141 reported in 2019. Among colon & rectal surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 521 payments — averaging $161.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Pharmaceuticals Incorporated$23K
- Baxter Healthcare$21K
- Intuitive Surgical$17K
- Biom'up SA$6K
- TELA Bio, Inc.$5K
- Medtronic$2K
- plus $10K from 32 others
Across 441 payments — averaging $3814.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$826K
- Gilead$337K
- Pfizer$298K
- F. Hoffmann-la Roche AG$120K
- Genentech, Inc.$59K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- plus $3K from 1 others
What the payments were for
- Consulting fees$18,27022%
- Speaking & faculty fees$25,39330%
- Travel & lodging$12,41415%
- Food & beverage$20,74525%
- Education$7,2669%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Pharmaceuticals Incorporated | 33 | $23,054 |
| Baxter Healthcare | 42 | $21,477 |
| Intuitive Surgical | 127 | $16,730 |
| Biom'up SA | 16 | $6,151 |
| TELA Bio, Inc. | 41 | $4,741 |
| Medtronic(2 entities) | 60 | $2,251 |
| Johnson & Johnson | 56 | $1,905 |
| AbbVie(2 entities) | 27 | $1,683 |
| Trevena, Inc. | 3 | $1,376 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $849 |
| Conmed Corporation | 14 | $623 |
| Sanara Medtech Inc. | 4 | $510 |
| Biom'up France SAS | 3 | $387 |
| Davol Inc. | 5 | $364 |
| Covidien LP | 5 | $344 |
| Shire North American Group Inc | 7 | $223 |
| Olympus America Inc. | 4 | $211 |
| Braintree Laboratories, Inc. | 10 | $198 |
| Axonics, Inc. | 5 | $183 |
| Lexington Medical, Inc. | 1 | $130 |
| Gilead | 1 | $119 |
| Pfizer | 1 | $99 |
| Redhill Biopharma Inc. | 1 | $98 |
| Shionogi Inc | 1 | $96 |
| Boston Scientific | 2 | $82 |
| Mimedx Group, Inc. | 1 | $40 |
| Kerecis Limited | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Acell, Inc. | 1 | $31 |
| Coopersurgical, Inc. | 1 | $31 |
| Dilon Technologies, Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $24 |
| Organogenesis Inc. | 1 | $21 |
| Cook Medical LLC | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Dova Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EXPAREL$22,870
- FLOSEAL$18,336
- TISSEEL$16,770
- Da Vinci Surgical System$13,503
- HEMOBLAST$5,982
- OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex)$1,534
- OviTex 2S$1,498
- No Related Product$1,260
- Olinvyk$1,250
- INTERSTIM$1,172
- Ovitex$952
- ECHELON ENDOPATH$840
- CellerateRx$510
- HemoBlast Bellows$387
- Echelon Circular$350
- STRATTICE$266
- SEPRAFILM$237
- VISTASEAL$224
- AIRSEAL$163
- Phasix Mesh$156
How this compares
$84,206 in reported general payments places this provider in the 90th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 26 | $1,802,697 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 106 | $5,203 |
| CholestyramineCholestyramine (With Sugar) | 31 | $3,033 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 61 | $995 |
| Ibuprofen | 50 | $503 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 33 | $449 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 24 | $274 |
| Hydrocortisone | 15 | $260 |
| Tramadol Hcl | 56 | $246 |
| Neomycin Sulfate | 35 | $199 |
| Metronidazole | 45 | $161 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $139 |
| Prednisone | 18 | $104 |
| Tamsulosin Hcl | 21 | $93 |
| Pantoprazole Sodium | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $849 | $1,802,69726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 200 colon & rectal surgery providers in Texas.
Other colon & rectal surgery in San Antonio
- Christopher de JesusSan Antonio$201K
- William LewisSan Antonio$85K
- Michael KellerSan Antonio$50K
- Maria Martinez UgarteSan Antonio$47K
- James PrietoSan Antonio$16K
- Rolando SaenzSan Antonio$15K
- Mario AlcantaraSan Antonio$14K
- Thiru LakshmanAustin$756K
- Diego Marines CopadoHouston$462K
- Bidhan DasSugar Land$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.